Business
OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination
OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025Under the symbol "OSRH" SEOUL, South Korea, Feb. 14, 2025
About this update from Osr Holdings, Inc.
[{"type":"text","content":"OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025Under the symbol \"OSRH\"\nSEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp. (the \"Company\")) and OSR Holdings Co., Ltd. (\"OSR\") announced today the completion of their business combination (the \"Business Combination\").\n\n \n \n \n \n \n \n\n \nThe Company now operates as \"OSR Holdings, Inc.\" following the successful completion of the Business Combination. Beginning on Tuesday, February 18, 2025, the common stock and warrants of the Company are expected to begin trading on the Nasdaq Stock Market LLC under the ticker symbols \"OSRH\" and \"OSRHW,\" respectively. \nAbout OSR Holdings, Inc.\nOSR Holdings, Inc. was a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Following the successful completion of the Business Combination, the Company now owns approximately 67% of the outstanding stock of OSR, and OSR stockholders holding an additional 22% of the outstanding OSR shares have entered into agreements with the Company providing for the acquisition by the Company of such shares via put/call provisions commencing in 2026.\nAbout OSR Holdings Co., Ltd.\nOSR is a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. OSR aims to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Its current operating businesses (through three wholly-owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer, (ii) developing design-augmented biologics for age-related and other degenerative diseases and (iii) neurovascular intervention medical device and systems distribution in Korea. OSR's vision is to acquire and operate a portfolio of innovative health-care related companies globally.\nForward Looking Statements\nThis communication includes \"forward-looking statements\" within the meaning of the \"safe harbor\" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified ...